Combination therapy with albumin and pentoxifylline protects against acute kidney injury during endotoxemic shock in mice.

Ren Fail

Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Denver, Aurora, Colorado 80045, USA.

Published: April 2010

Endotoxemic shock is associated with approximately 50% incidence of acute kidney injury (AKI) and 70% mortality. Experimental studies indicate that endotoxemia-related AKI is associated with both hemodynamic and proinflammatory perturbations. We hypothesize that combined administration of albumin with pentoxifylline may protect against the development of AKI during endotoxemic shock in mice by maintaining the integrity of arterial circulation and exerting anti-inflammatory properties. We tested this hypothesis using an endotoxemic shock model produced by administering a high dose of lipopolysaccharide (LPS) (15 mg/kg intraperitoneal). LPS-treated mice developed hypotension compared to control mice (mean arterial pressure [MAP] 65.6 +/- 2.2 vs. 85.7 +/- 0.8 mm Hg, p < 0.05). Normal saline did not attenuate LPS-related hypotension (62.7 +/- 2.2 vs. 65.6 +/- 2.2 mm Hg, NS). Pentoxifylline, a phosphodiesterase inhibitor, worsened the LPS-related hypotension (50.7 +/- 6.9 vs. 65.6 +/- 2.2 mm Hg, p = 0.15) in a non-significant manner. Albumin alone caused a significant increase in MAP (79.3 +/- 4.7 vs. 62.7 +/- 2.2 mm Hg, p = 0.02), but had a non-significant modest effect on glomerular filtration rate (GFR; 60.8 +/- 24.7 vs. 38.2 +/- 18.2 microl/min, NS) compared to normal saline. However, the combination of albumin and pentoxifylline profoundly protected GFR (148.6 +/- 28.7 microl/min, vs. 38.2 +/- 18.2 microl/min, p < 0.01) as compared to normal saline. The combined administration of albumin and pentoxifylline significantly attenuated the renal iNOS protein expression and increased cardiac output. In summary, neither normal saline nor albumin nor pentoxifylline alone protected against endotoxemic shock-related AKI. However, the combination of albumin and pentoxifylline was effective in preventing AKI during endotoxemic shock. Thus, in endotoxemic shock, a multifactorial approach involving hemodynamic and anti-inflammatory effect may be necessary to decrease AKI.

Download full-text PDF

Source
http://dx.doi.org/10.3109/08860220903180632DOI Listing

Publication Analysis

Top Keywords

albumin pentoxifylline
24
endotoxemic shock
24
normal saline
16
+/-
12
656 +/-
12
acute kidney
8
kidney injury
8
shock mice
8
combined administration
8
administration albumin
8

Similar Publications

Objectives: This randomized, double-blind, placebo-controlled clinical trial aimed to prospectively examine the effect of pentoxifylline (PTX) on hypoxia-inducible factor-2 alpha (HIF-2α) and its role in controlling anemia in hemodialysis (HD) patients.

Methods: Eighty patients on HD were randomized to receive 400 mg of PTX or placebo twice daily for 6 months. The hemoglobin (Hb) and other hematologic parameters, the weekly erythropoiesis-stimulating agents (ESAs), and the ESA resistance index (ERI) were assessed monthly during the study.

View Article and Find Full Text PDF

Diabetic Kidney Disease (DKD), a frequent consequence of diabetes, has substantial implications for both morbidity and mortality rates, prompting the exploration of new metabolic biomarkers due to limitations in current methods like creatinine and albumin measurements. Pentraxin 3 (PTX3) shows promise for assessing renal inflammation in DKD. This study investigates how DKD metabolites could influence PTX3 expression through molecular docking, ADMET profiling, and dynamic simulation.

View Article and Find Full Text PDF

Aims: To investigate the efficacy and safety of tadalafil (TAD) versus pentoxifylline (PTX) in the management of diabetic kidney disease (DKD). Some animal studies and clinical trials reported that tadalafil and pentoxifylline have a reducing effect on different blood glucose parameters and lipid profiles which contribute to progress the patients with diabetes mellitus (DM) to DKD.

Methods: From February 2022 to March 2023, 90 patients with type 2 DM and DKD (micro-albuminuria) were enrolled in this randomized-controlled study.

View Article and Find Full Text PDF

Objective: To explore the efficacy of dapagliflozin plus pentoxifylline in the treatment of early diabetic nephropathy and its effect on serum inflammatory factors and immune function.

Methods: A total of 90 patients with early diabetic nephropathy who were admitted to Cangzhou Central Hospital from January 2019 to January 2022 were recruited and randomized (1:1) into a control group and an observation group using the random number table method. The control group was treated with dapagliflozin, and the observation group was treated with pentoxifylline plus dapagliflozin.

View Article and Find Full Text PDF

Background: Occupational and environmental exposure to chromium compounds such as potassium dichromate (PDC) (KCrO) has emerged as a potential aetiologic cause for renal disease through apoptotic, and inflammatory reactions. The known potent antioxidants such as nicorandil (NIC) and/or pentoxifylline (PTX) were studied for their possible nephroprotective effect in PDC-treated rats.

Methods: Forty male Wistar rats were divided into five groups; control, PDC group, NIC+PDC, PTX+PDC group, and combination+PDC group.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!